A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 3,63 (+17,86%). A mediana é € 3,46 (+12,34%).
| Comprar |
9 |
| Manter |
13 |
| Vender |
2 |
Notícias Ir para o feed de notícias
GoodRx launches Companion family health subscription and will offer it as employer benefit in 2027
GoodRx introduced Companion, a family healthcare subscription that provides free access to 250 generic medications and discounted telehealth, vision, dental and lab services for $24.99 per month (individual plan $14.99). The company plans to make Companion available as an employer-offered benefit starting January 1, 2027, with employers able to subsidize employee costs. GoodRx reported 39% year-over-year growth in subscription revenue in Q2 and said Companion uptake has exceeded expectations. » Mais em finance.yahoo.com
GoodRx: shareholders approve three directors, KPMG as auditor and executive compensation
At the GoodRx annual meeting, shareholders voted to elect class‑III directors Wendy Barnes, Ronald E. Bruehlman and Gregory Mondre and to appoint KPMG as independent auditors for fiscal year 2026. In a non‑binding vote, shareholders also approved the performance‑based compensation for the named executives. GoodRx reported Q1 2026 EPS of $0.07 (plan met) and revenue of $194 million (4.7% above expectations) and introduced a monthly subscription offering, "GoodRx Companion," for $14.99. » Mais em de.investing.com
GoodRx launches $14.99-a-month Companion subscription to boost recurring revenue
GoodRx introduced Companion, a $14.99/month subscription aimed at patients with chronic conditions that combines savings on more than 200 common generic medications with discounted dental services and $19 telehealth visits for routine issues. The service expands GoodRx’s subscription strategy and creates a more predictable recurring revenue stream by engaging consumers beyond one-off prescription transactions. Companion also offers lower-cost access to exams, cleanings, X-rays and other dental care. » Mais em finance.yahoo.com
Dados financeiros da empresa
| (EUR) | junho de 2026 | |
|---|---|---|
| Receitas | 175,6 mi | 1,92% |
| Ganho bruto | 157,2 mi | 9,00% |
| Ganho líquido | 7,48 mi | 31,36% |
| EBITDA | 22,15 mi | 47,83% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 1,02 bi |
Número de ações | 346,63 mi |
Máximo/mínimo de 52 semanas | € 5,03 - € 1,53 |
| Dividendos | Não |
Beta | 1,60 |
PER (PE Ratio) | 64,45 |
PEG (PEG Ratio) | -1,15 |
P/VC (PB Ratio) | 1,78 |
P/V (PS Ratio) | 1,50 |
Perfil da empresa
GoodRx Holdings, Inc. bietet über seine Tochtergesellschaften Informationen und Tools an, die es den Verbrauchern ermöglichen, Preise zu vergleichen und beim Kauf von verschreibungspflichtigen Medikamenten in den Vereinigten Staaten zu sparen. Das Unternehmen betreibt eine Preisvergleichsplattform, die Verbrauchern kuratierte, geografisch relevante Preise für verschreibungspflichtige Medikamente und Zugang zu ausgehandelten Preisen über GoodRx-Codes bietet, mit denen sie bei Verschreibungen in den Vereinigten Staaten Geld sparen können. Das Unternehmen bietet auch andere Produkte und Dienstleistungen im Gesundheitswesen an, darunter Abonnements, Lösungen für Pharmahersteller und telemedizinische Dienstleistungen. Es dient Pharmacy Benefit Managern, die Rezepturen und Verschreibungstransaktionen verwalten, einschließlich der Festlegung von Preisen zwischen Verbrauchern und Apotheken. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Santa Monica, Kalifornien.
| Nome | GOODRX HOLDINGS INC. CL.A |
| CEO | Wendy Barnes |
| Sede | Santa Monica,
ca EUA |
| Site | |
| Setor | Indústria |
| Indústria | Serviços profissionais |
| Entrada em bolsa | 23/09/2020 |
| Colaboradores | 697 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | GDRX |